Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotype.

Lazzeroni M, Guerrieri-Gonzaga A, Botteri E, Leonardi MC, Rotmensz N, Serrano D, Varricchio C, Disalvatore D, Del Castillo A, Bassi F, Pagani G, DeCensi A, Viale G, Bonanni B, Pruneri G.

Br J Cancer. 2013 Apr 30;108(8):1593-601. doi: 10.1038/bjc.2013.147. Epub 2013 Apr 11.

2.

Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study.

Guerrieri-Gonzaga A, Lazzeroni M, Botteri E, Serrano D, Rotmensz N, Varricchio MC, Cazzaniga M, Bollani G, Mora S, Montefrancesco C, Pruneri G, Viale G, Intra M, Galimberti V, Goldhirsch A, Bagnardi V, Bonanni B, DeCensi A.

Ann Oncol. 2013 Jul;24(7):1859-66. doi: 10.1093/annonc/mdt113. Epub 2013 Mar 26.

PMID:
23532115
3.

Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: results of a large observational study.

Guerrieri-Gonzaga A, Botteri E, Lazzeroni M, Rotmensz N, Goldhirsch A, Varricchio C, Serrano D, Cazzaniga M, Bassi F, Luini A, Bagnardi V, Viale G, Mora S, Bollani G, Albertazzi E, Bonanni B, Decensi A.

Ann Oncol. 2010 May;21(5):949-54. doi: 10.1093/annonc/mdp408. Epub 2009 Oct 25.

PMID:
19858087
4.

Prognostic impact of Ki-67 labeling indices with 3 different cutoff values, histological grade, and nuclear grade in hormone-receptor-positive, HER2-negative, node-negative invasive breast cancers.

Ono M, Tsuda H, Yunokawa M, Yonemori K, Shimizu C, Tamura K, Kinoshita T, Fujiwara Y.

Breast Cancer. 2015 Mar;22(2):141-52. doi: 10.1007/s12282-013-0464-4. Epub 2013 Apr 13.

PMID:
23584595
5.

Ductal intraepithelial neoplasia: postsurgical outcome for 1,267 women cared for in one single institution over 10 years.

Guerrieri-Gonzaga A, Botteri E, Rotmensz N, Bassi F, Intra M, Serrano D, Renne G, Luini A, Cazzaniga M, Goldhirsch A, Colleoni M, Viale G, Ivaldi G, Bagnardi V, Lazzeroni M, Decensi A, Veronesi U, Bonanni B.

Oncologist. 2009 Mar;14(3):201-12. doi: 10.1634/theoncologist.2008-0203. Epub 2009 Mar 5.

6.

Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.

Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, Maiorano E, MacGrogan G, Braye SG, Ohlschlegel C, Neven P, Orosz Z, Olszewski WP, Knox F, Thürlimann B, Price KN, Castiglione-Gertsch M, Gelber RD, Gusterson BA, Goldhirsch A; Breast International Group Trial 1-98.

J Clin Oncol. 2008 Dec 1;26(34):5569-75. doi: 10.1200/JCO.2008.17.0829. Epub 2008 Nov 3.

7.

Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer.

Munzone E, Botteri E, Sciandivasci A, Curigliano G, Nolè F, Mastropasqua M, Rotmensz N, Colleoni M, Esposito A, Adamoli L, Luini A, Goldhirsch A, Viale G.

Breast Cancer Res Treat. 2012 Jul;134(1):277-82. doi: 10.1007/s10549-012-2040-6. Epub 2012 Apr 1.

PMID:
22467243
8.

Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.

Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn HJ; Panel Members.

Ann Oncol. 2015 Aug;26(8):1533-46. doi: 10.1093/annonc/mdv221. Epub 2015 May 4.

9.

Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting.

Habel LA, Achacoso NS, Haque R, Nekhlyudov L, Fletcher SW, Schnitt SJ, Collins LC, Geiger AM, Puligandla B, Acton L, Quesenberry CP Jr.

Breast Cancer Res. 2009;11(6):R85. doi: 10.1186/bcr2453. Epub 2009 Nov 18.

10.

Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.

Papantoniou V, Sotiropoulou E, Valsamaki P, Tsaroucha A, Sotiropoulou M, Ptohis N, Stipsanelli A, Dimitrakakis K, Marinopoulos S, Tsiouris S, Antsaklis A.

Breast Cancer. 2011 Oct;18(4):286-91. doi: 10.1007/s12282-009-0192-y. Epub 2010 Feb 9.

PMID:
20143189
11.

Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial.

Decensi A, Puntoni M, Pruneri G, Guerrieri-Gonzaga A, Lazzeroni M, Serrano D, Macis D, Johansson H, Pala O, Luini A, Veronesi P, Galimberti V, Dotti MC, Viale G, Bonanni B.

Cancer Prev Res (Phila). 2011 Aug;4(8):1181-9. doi: 10.1158/1940-6207.CAPR-10-0337. Epub 2011 Jun 17.

12.

Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ.

Zammit C, Yelland A, Deutsch G.

Lancet. 2003 Oct 4;362(9390):1154; author reply 1155-6. No abstract available.

PMID:
14550708
13.

A review of the management of ductal carcinoma in situ following breast conserving surgery.

Boxer MM, Delaney GP, Chua BH.

Breast. 2013 Dec;22(6):1019-25. doi: 10.1016/j.breast.2013.08.012. Epub 2013 Sep 23. Review.

PMID:
24070852
14.

Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.

Allred DC, Anderson SJ, Paik S, Wickerham DL, Nagtegaal ID, Swain SM, Mamounas EP, Julian TB, Geyer CE Jr, Costantino JP, Land SR, Wolmark N.

J Clin Oncol. 2012 Apr 20;30(12):1268-73. doi: 10.1200/JCO.2010.34.0141. Epub 2012 Mar 5.

15.

Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ.

Baroni G, Pedotti A, Orecchia R.

Lancet. 2003 Oct 4;362(9390):1155; author reply 1155-6. No abstract available.

PMID:
14550709
16.

Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ.

Cunnick GH, Mokbel K.

Lancet. 2003 Oct 4;362(9390):1154; author reply 1155-6. No abstract available.

PMID:
14550707
17.

Hormonal receptor status, Ki-67 and HER2 expression: Prognostic value in the recurrence of ductal carcinoma in situ of the breast?

Poulakaki N, Makris GM, Battista MJ, Böhm D, Petraki K, Bafaloukos D, Sergentanis TN, Siristatidis C, Chrelias C, Papantoniou N.

Breast. 2016 Feb;25:57-61. doi: 10.1016/j.breast.2015.10.007. Epub 2015 Nov 21.

PMID:
26612082
18.

High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer.

Criscitiello C, Disalvatore D, De Laurentiis M, Gelao L, Fumagalli L, Locatelli M, Bagnardi V, Rotmensz N, Esposito A, Minchella I, De Placido S, Santangelo M, Viale G, Goldhirsch A, Curigliano G.

Breast. 2014 Feb;23(1):69-75. doi: 10.1016/j.breast.2013.11.007. Epub 2013 Dec 4.

PMID:
24314620
19.

Breast conservative surgery for well-differentiated ductal intraepithelial neoplasia: Risk factors for ipsilateral breast tumor recurrence.

Toesca A, Botteri E, Lazzeroni M, Vila J, Manika A, Ballardini B, Bettarini F, Guerrieri-Gonzaga A, Bonanni B, Rotmensz N, Viale G, Veronesi P, Luini A, Veronesi U, Gentilini O.

Breast. 2014 Dec;23(6):829-35. doi: 10.1016/j.breast.2014.08.016. Epub 2014 Sep 26.

PMID:
25261930
20.

HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ.

Rakovitch E, Nofech-Mozes S, Hanna W, Narod S, Thiruchelvam D, Saskin R, Spayne J, Taylor C, Paszat L.

Br J Cancer. 2012 Mar 13;106(6):1160-5. doi: 10.1038/bjc.2012.41. Epub 2012 Feb 23.

Supplemental Content

Support Center